Wilms tumor 1–derived peptide–MHC class II complex (WT1-MHC II)

The Wilms tumor 1 (WT1)–derived peptide–MHC class II complex is a molecular assembly found on the surface of professional antigen-presenting cells (APCs) and certain tumor cells. It consists of a specific peptide fragment derived from the WT1 protein—a zinc-finger transcription factor that is highly overexpressed in various hematological malignancies and solid tumors—bound to the peptide-binding groove of a Major Histocompatibility Complex (MHC) class II molecule, such as HLA-DR, HLA-DP, or HLA-DQ [1, 2]. This complex serves as the primary ligand for the T-cell receptors (TCRs) of CD4+ helper T lymphocytes. Recognition of the WT1-MHC II complex by CD4+ T cells is a critical step in the induction of a comprehensive anti-tumor immune response, as these cells provide essential signals for the activation and memory formation of CD8+ cytotoxic T cells and the recruitment of other immune effectors [3, 4]. In clinical oncology, this complex is a major target for immunotherapy. Therapeutic strategies include peptide vaccines like Galinpepimut-S, which contains WT1 sequences designed to be presented on both MHC class I and II molecules to elicit a dual CD4+/CD8+ T-cell response [5]. Additionally, researchers are developing TCR-engineered T-cell therapies and TCR-like antibodies that specifically recognize these pMHC complexes to bypass the need for natural antigen processing. While WT1 is a potent tumor antigen, safety considerations include monitoring for potential off-target effects in normal tissues that express low levels of WT1, such as the kidneys and hematopoietic stem cells [1, 6].

Other names

WT1-HLA class II complexWT1-HLA-DR complexWT1 peptide-MHC II complexWilms tumor protein-derived peptide-MHC class II complexWT1-HLA-DP complexWT1-HLA-DQ complex

Activation of antigen-specific CD4+ helper T cells to coordinate an anti-tumor immune response and provide essential help for CD8+ cytotoxic T-cell activity and memory formation.